Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bearish calls are justified. Keeping that in mind, here are three stocks facing legitimate challenges and some alternatives worth exploring instead.
Baxter (BAX)
Consensus Price Target: $21.54 (4.8% implied return)
With a history dating back to 1931 and products used in over 100 countries, Baxter International (NYSE: BAX) provides essential healthcare products including dialysis therapies, IV solutions, infusion systems, surgical products, and patient monitoring technologies to hospitals and clinics worldwide.
Why Do We Think BAX Will Underperform?
- Constant currency revenue growth has disappointed over the past two years and shows demand was soft
- Performance over the past five years shows each sale was less profitable, as its earnings per share fell by 7.2% annually
- Negative returns on capital show management lost money while trying to expand the business
At $20.55 per share, Baxter trades at 10.4x forward P/E. Dive into our free research report to see why there are better opportunities than BAX.
Royalty Pharma (RPRX)
Consensus Price Target: $59.25 (6.5% implied return)
Pioneering a unique business model in the pharmaceutical industry since 1996, Royalty Pharma (NASDAQ: RPRX) acquires rights to receive portions of sales from successful biopharmaceutical products, providing funding to drug developers without conducting research itself.
Why Are We Wary of RPRX?
- Annual revenue growth of 2.1% over the last five years was below our standards for the healthcare sector
- Revenue base of $2.44 billion puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 2.9 percentage points
Royalty Pharma is trading at $55.66 per share, or 10.4x forward P/E. To fully understand why you should be careful with RPRX, check out our full research report (it’s free).
Korn Ferry (KFY)
Consensus Price Target: $79.25 (8% implied return)
With clients including 97% of the S&P 100 and operations in 103 offices across 51 countries, Korn Ferry (NYSE: KFY) is a global consulting firm that helps organizations design optimal structures, recruit talent, develop leaders, and create effective compensation strategies.
Why Does KFY Worry Us?
- Flat sales over the last two years suggest it must find different ways to grow during this cycle
- Free cash flow margin shrank by 5.3 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
- Shrinking returns on capital suggest that increasing competition is eating into the company’s profitability
Korn Ferry’s stock price of $73.38 implies a valuation ratio of 13.1x forward P/E. If you’re considering KFY for your portfolio, see our FREE research report to learn more.
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
